The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. 37% of trial volunteers are from racial and ethnic minorities.

Clinical Trials 52

Clinical Trials Vaccine Trials FDA Approval 52

The Pharma Data

NOVEMBER 20, 2020

November 20, 2020 — The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 10 to discuss the request for emergency use authorization (EUA) of a COVID-19 vaccine from Pfizer, Inc. Source: FDA. Posted: November 2020.

Vaccine 52

Vaccine FDA FDA Approval Production 52

The Pharma Data

DECEMBER 11, 2020

11, 2020 – The U.S. Food and Drug Administration is expected to approve emergency use of Pfizer’s coronavirus vaccine as early as Saturday after its advisory panel cleared the way for the start of a national campaign to inoculate Americans and stem the spread of COVID-19. FRIDAY, Dec. Initially, a shipment of 2.9

Vaccine 52

Vaccine FDA Hospitals Doctors 52

The Pharma Data

NOVEMBER 9, 2020

09, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

NOVEMBER 30, 2020

30, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Novavax will use vaccine material produced at commercial scale for this trial. GAITHERSBURG, Md.,

Clinical Development 52

Clinical Development Vaccine Clinical Trials Immune Response 52

The Pharma Data

JUNE 6, 2022

Priorix becomes an additional source of measles, mumps and rubella vaccine for US patients. 4] The report also noted 400,000 fewer children entered kindergarten in the 2020-2021 school year than expected nationally, meaning those children may not be up to date on childhood immunisations like their MMR vaccination. [4].

FDA Approval 52

FDA Approval Vaccine FDA Disease 52

The Pharma Data

DECEMBER 10, 2020

10, 2020 – A U.S. Food and Drug Administration advisory panel will vote on Thursday whether to recommend emergency approval of Pfizer’s coronavirus vaccine, a decision that will come not a moment too soon as the country reported more than 3,000 new COVID-19 deaths on Wednesday. THURSDAY, Dec. Meanwhile, U.S.

Vaccine 52

Vaccine FDA Hospitals Doctors 52

The Pharma Data

JANUARY 6, 2021

6 January 2021 — AstraZeneca’s COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the active immunisation of adults. Additional safety and efficacy data will continue to accumulate from ongoing clinical trials.

Vaccine 52

Vaccine Virus Clinical Trials Government 52

The Pharma Data

DECEMBER 30, 2020

The year 2020 will certainly go down in history as the year of COVID-19. Gilead Sciences Makes Multiple Bets : When Gilead Sciences wasn’t working on remdesivir in COVID-19, the company seemed to be constantly flexing its M&A muscle over the course of 2020. It began in May with the $4.9 But the U.K.-based

Science 52

Science Pharmaceuticals Disease FDA Approval 52

The Pharma Data

AUGUST 14, 2020

In other news, Genentech’s Evrysdi (risdiplam) has secured FDA approval for the treatment of spinal muscular atrophy and Bristol Myers Squibb has announced positive data from two Phase 3 clinical trials of its drug Opdivo. AstraZeneca seals manufacturing deal to deliver COVID-19 vaccine in China.

FDA Approval 52

FDA Approval Vaccine Clinical Trials FDA 52

The Pharma Data

DECEMBER 18, 2020

18, 2020 /PRNewswire/ — Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SILVER SPRING, Md. , Hahn , M.D.

Vaccine 52

Vaccine FDA Clinical Trials FDA Approval 52

The Pharma Data

DECEMBER 10, 2020

11, 2020 02:48 UTC. –( BUSINESS WIRE )– ImmunityBio , a privately-held immunotherapy company, today announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates against coronavirus (SARS-CoV-2) in a challenge study. CULVER CITY, Calif.–(

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

FEBRUARY 1, 2021

This approval expands Biogen’s industry-leading portfolio of MS treatments, which also includes the subcutaneous (SC) administration of Plegridy, and follows the European Commission’s marketing authorization for the IM administration in December 2020. “At MS, the coronavirus and vaccines – updated global advice. Source link.

FDA Approval 40

FDA Approval FDA Clinical Trials Biosimilars 40

The Pharma Data

NOVEMBER 16, 2020

16, 2020– Moderna, Inc. We are pleased to submit these extended stability conditions for mRNA-1273 to regulators for approval. Room Temperature for Vaccination: Once the vaccine is removed from the refrigerator for administration, it can be kept at room temperature conditions for up to 12 hours. CAMBRIDGE, Mass.–(BUSINESS

Vaccine 52

Vaccine Pharmacy FDA Clinical Trials 52

The Pharma Data

DECEMBER 3, 2020

4, 2020 08:00 UTC. The Phase 1 trial was a randomized, observer-blind, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of the adjuvanted COVID-19 S-Trimer vaccine candidates formulated with different antigen levels. No serious adverse events related to the vaccine candidates studied were reported.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

JANUARY 15, 2021

Food and Drug Administration (FDA) approval of Darzalex Faspro ® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] Janssen Biotech, Inc.

FDA Approval 52

FDA Approval FDA Treatment Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 20, 2020

. Based on current projections, the companies expect to produce globally up to 50 million doses in 2020 and up to 1.3 billion doses by the end of 2021; the companies will be ready to distribute the vaccine within hours after authorization. by the middle to end of December 2020. participants are 56-85 years of age.

Vaccine 52

Vaccine FDA Clinical Trials Trials 52

The Pharma Data

DECEMBER 11, 2020

Friday, December 11, 2020. FDA authorizes COVID-19 mRNA vaccine for emergency use; companies are prepared to deliver first doses in the U.S. Government to supply doses in 2020 & 2021. Pfizer and BioNTech expect to file a Biologics License Application for possible full regulatory approval in 2021.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

EG Life Sciences

FEBRUARY 15, 2023

The US Food and Drug Administration (FDA) approved around 26 novel drugs in 2022. Approval processes were slow in comparison to 2020 and 2021, where 53 and 50 approvals were achieved respectively. Going into the third year of the pandemic, we know that the virus still impacts industry operations.

Drug Development 52

Drug Development FDA Approval Virus Drugs 52

The Pharma Data

JANUARY 9, 2021

Reports preliminary 2020 total revenues of $1.55 billion at the midpoint and Adjusted EBITDA of $635 million at the midpoint, both at or above prior guidance given in November 2020. NYSE:EBS) today announced its financial forecast for 2021 and selected preliminary unaudited financial results for 2020.

Government 52

Government Vaccine Production Licensing 52

The Pharma Data

DECEMBER 13, 2020

14, 2020 /PRNewswire/ — Today, the U.S. Food and Drug Administration (FDA) approved a first-of-its-kind intentional genomic alteration (IGA) in a line of domestic pigs, referred to as GalSafe pigs, which may be used for food or human therapeutics. The FDA, an agency within the U.S. .

FDA Approval 52

FDA Approval FDA Production Vaccine 52

Codon

AUGUST 26, 2024

He also explains how they could be used to combat pandemics on “day zero,” well before vaccines are developed. After the outbreak ended, it took another three years for the first Ebola vaccine by Merck to be approved. Timelines for vaccine development are shrinking, but can it move even faster?

RNA 93

RNA Virus DNA Vaccine 93

The Pharma Data

DECEMBER 10, 2020

Thursday, December 10, 2020 – . Data from 43,448 participants, half of whom received BNT162b2 and half of whom received placebo, showed that the vaccine candidate was well tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection 7 days or more after the second dose.

Vaccine 52

Vaccine Trials Clinical Trials Therapies 52

The Pharma Data

NOVEMBER 16, 2020

16, 2020– Moderna, Inc. The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. All 11 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group. .–(BUSINESS WIRE)–Nov.

Vaccine 52

Vaccine FDA Clinical Trials Disease 52

The Pharma Data

DECEMBER 8, 2020

8, 2020– Moderna, Inc., Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the Swiss Federal Government has increased its confirmed order commitment from 4.5 8, 2020– Moderna, Inc.,

Vaccine 40

Vaccine RNA Government Clinical Trials 40

The Pharma Data

NOVEMBER 9, 2020

NEW YORK & MAINZ, GERMANY–(BUSINESS WIRE) November 9, 2020. Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis. Pfizer Inc. Today is a great day for science and humanity.

Vaccine 40

Vaccine Clinical Trials Trials FDA 40

The Pharma Data

NOVEMBER 18, 2021

Worldwide, it’s estimated there were further than new cases of order cancer diagnosed and further than deaths from the complaint in 2020. Utmost cases of RCC are discovered apropos during imaging tests for other abdominal conditions. In theU.S., About Merck’s Beforehand-Stage Cancer Clinical Program. About Merck.

FDA Approval 52

FDA Approval FDA Therapies Treatment 52

The Pharma Data

JULY 29, 2021

It is approved for paediatric use in SEA from ages six to 17 in Europe, the US and several other markets. In the US, Japan, Canada and a number of other markets, it is approved for use in adult patients with EGPA. It is not currently approved for use in COPD anywhere in the world. Consider vaccination if medically appropriate.

FDA Approval 52

FDA Approval FDA Clinical Trials Treatment 52

The Pharma Data

APRIL 7, 2023

“Fundamentally, however, the touchstone of FDA drug approval is a favorable benefit-risk assessment; without that favorable assessment, the drug should not have the status of being FDA-approved.” The agency’s approval included a requirement that the sponsor conduct a post marketing confirmatory study.

FDA 40

FDA FDA Approval Production Vaccine 40

The Pharma Data

OCTOBER 14, 2020

15, 2020 10:00 UTC. Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Vaccine 52

Vaccine Trials FDA Clinical Trials 52

The Pharma Data

OCTOBER 29, 2020

Data support baricitinib’s ongoing Phase 3 program and potential to be the first approved medicine for people living with alopecia areata (AA). . VACCINATIONS : Avoid use of live vaccines with Olumiant. 1 Olumiant Prescribing Information, 2020. INDIANAPOLIS , Oct. 2 Walker JG and Smith MD. J Rheumatol.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

The Pharma Data

DECEMBER 20, 2020

Food and Drug Administration (FDA) is plenty busy with COVID-19 vaccine Emergency Use Authorizations (EUAs) this month, but they’re also wrapping up the year with a few PDUFA dates for other therapies. It was approved on December 15, 2020. The FDA completed a class 2 response in July 2020. Here’s a look.

FDA 52

FDA FDA Approval Licensing Licensing 52

The Pharma Data

NOVEMBER 12, 2020

12 November 2020 — The CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised with respiratory symptoms of COVID-19 did not meet the primary efficacy endpoint. Accessed October 2020. Accessed October 2020. Posted: November 2020. NCT identifier: NCT04380688. Available online.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

A leader in this critical effort is NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV ) initiative, a public-private partnership involving 20 biopharmaceutical companies, academic experts, and multiple federal agencies. Vaccines Working Group : Accelerates the evaluation of vaccine candidates.

Clinical Trials 52

Clinical Trials Hospitals Vaccine Trials 52

Agency IQ

DECEMBER 1, 2023

BY RACHEL COE, MSC | NOV 27, 2023 8:24 PM CST FDA’s transition away from public health emergency (PHE)-related guidance documents The Covid-19 Public Health Emergency (PHE) was activated on January 31, 2020. supplemental oxygen, mechanical ventilation). Like the first version, the updated guidance was issued as direct-to-final.

FDA 40

FDA Clinical Trials Vaccine Trials 40

The Pharma Data

NOVEMBER 17, 2021

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. In May 2020, they published a study in mice demonstrating that disulfiram reduced inflammation caused by sepsis by blocking a key protein involved in the process.

Virus 52

Virus Drugs Clinical Trials Medical Schools 52

The Pharma Data

JUNE 18, 2021

First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, 1,2,3,4,5,6,7 including seven responsible for 40% of pneumococcal disease cases and deaths in the U.S. Following today’s FDA approval, the U.S. Jansen, Ph.D.,

Vaccine 52

Vaccine FDA Approval FDA Disease 52